MOTS-c: Research Profile of a Mitochondrial-Derived Peptide in Metabolic and Cardiopulmonary Models

What MOTS-c is

MOTS-c (mitochondrial ORF of the 12S rRNA type-c) is described in the literature as a mitochondrial-derived peptide composed of 16 amino acids encoded within the 12S ribosomal RNA region of the mitochondrial genome. A review synthesis notes that the peptide is co-expressed with mitochondria across different tissues and is also detectable in plasma, where circulating levels have been reported to decline with age. Reviews further describe that, under metabolic stress, the peptide has been observed to translocate to the nucleus and be associated with regulation of nuclear gene expression.

How the research studies it

MOTS-c has been studied chiefly across metabolic, cardiovascular, cardiopulmonary, and exercise-physiology research areas. Model systems in the cited literature span in vitro pulmonary microvascular endothelial cell work, rodent models (including streptozotocin-induced type 1 diabetic mice and endurance-trained mice), and human observational sampling — a prospective controlled cohort of 107 patients undergoing cardiopulmonary bypass, and comparisons of marathon runners with sedentary subjects.

The overall evidence base remains early-stage and predominantly preclinical. A review of the peptide explicitly notes that MOTS-c has been applied infrequently in disease treatment and that no established method for clinical application has been developed, framing much of the current work as mechanistic and exploratory rather than clinically validated.

What the strongest research examines

In a study combining a prospective controlled trial of 107 cardiopulmonary-bypass patients with in vivo and in vitro experiments, plasma MOTS-c concentrations were reported to be lower in patients with acute lung injury, and MOTS-c pretreatment was associated with altered glycolytic flux, reduced oxidative stress, and suppressed ferroptosis in pulmonary microvascular endothelial cells, described via an AMPK–HIF-1α–PFKFB3 pathway. In an endurance-exercise study of marathon runners, sedentary subjects, and endurance-trained mice, serum MOTS-c levels were associated with aerobic exercise capacity, and endurance training was linked to increased MOTS-c secretion alongside activation of the AMPK/PGC-1α pathway and changes in skeletal muscle mitochondrial respiration.

In a streptozotocin-induced type 1 diabetic mouse model of diabetic cardiomyopathy, subcutaneous MOTS-c administration over 12 weeks was associated with changes in cardiac function and structure, reactivation of AMPK signaling, and reduced inflammatory markers relative to untreated diabetic mice. A review synthesis summarizes these and related lines of work, noting that MOTS-c has been examined in the context of glucose metabolism in skeletal muscle and discussed in relation to aging, cardiovascular disease, insulin resistance, and inflammation, while cautioning that clinical translation has not been established. Taken together, the cited findings are largely mechanistic and model-specific, and human data are limited to observational associations.

What the research does not show

The human evidence identified in this search is limited in scale; larger controlled trials establishing exposure and long-term safety in humans are not yet available.